{"id":237673,"date":"2026-09-09T12:57:44","date_gmt":"2026-09-09T07:27:44","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=237673"},"modified":"2026-09-09T12:57:44","modified_gmt":"2026-09-09T07:27:44","slug":"is-beta-drugs-a-good-buy-after-q1-fy27-results","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/is-beta-drugs-a-good-buy-after-q1-fy27-results\/","title":{"rendered":"Is Beta Drugs a Good Buy After Its Q1 FY27 Results?"},"content":{"rendered":"

Beta Drugs share price around Rs 2,113. 24.7% below 52-week high of Rs 2,808. Q1 FY27 revenue Rs 127 crore, up 23.2% YoY. PAT Rs 16 crore, up 40.9%. PE 51x.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Beta Drugs’ Q1 FY27 results were strong, with revenue at Rs 127 crore and PAT climbing 41% to Rs 16 crore. The stock trades at a PE of 51x against an industry average near 38x, so some of this good news is already priced in. The Beta Drugs share price near Rs 2,113 reflects that optimism, so investors weighing whether Beta Drugs is a good buy today should focus on whether this pace of growth can be sustained rather than just this quarter’s print.<\/p>\n<\/p><\/div>\n

The Beta Drugs share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Beta Drugs is a manufacturer of oncology injectables and specialty formulations, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.<\/p>\n

Revenue for the quarter came in at Rs 127 crore, up 23.2% year on year, while profit after tax came in at Rs 16 crore, up 40.9% from a year earlier. That combination of numbers is exactly what this article breaks down, along with what it means for the Beta Drugs share price from here.<\/p>\n

This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the Beta Drugs share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n